The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities - PubMed
4 hours ago
- #CAR T-cell therapy
- #autoimmune neurology
- #refractory diseases
- CAR T-cell therapies, originally used in hematologic cancers, show promising and sustained benefits in refractory autoimmune neurological diseases, including Myasthenia Gravis and multiple sclerosis.
- Treatment targets CD19-positive plasma cells and plasmablasts, leading to impressive, long-lasting, drug-free clinical improvements with potential immune reset, without needing continued immunotherapy cycles.
- CAR T therapy is most suitable in early stages of disability development, at early-active/refractory status, rather than late disease progression when deficits may be irreversible.
- These therapies cross the blood-brain barrier, expand as 'living cells' to memory cells, and exert effects beyond B cells, offering sustained long-term benefits and a path toward a cure.
- Key uncertainties and challenges include the duration of drug-free remissions, logistical issues, economic limitations, and the need for collaborative efforts in specialized clinical centers.